Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/28/2026, 12:00:00 AM
Announced that the U.S. FDA approved Breztri Aerosphere for the maintenance treatment of asthma in patients 12 years and older, making it the first single-inhaler triple-combination therapy approved for this indication in the US. Low importance as the market impact for supplemental indications is typically 1-5%.
Korean Translation
미국 FDA가 12세 이상 환자의 천식 유지 요법으로 브레즈트리 에어로스피어(Breztri Aerosphere)를 승인했다고 발표함. 이는 미국에서 해당 적응증으로 승인된 최초의 단일 흡입기 3제 복합 요법임. 추가 적응증 승인에 따른 시장 영향력이 1-5% 수준일 것으로 예상되어 낮은 중요도로 분류됨.
Related Recent Events
DICK'S Sporting Goods Inc (DKS) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-27. Medium importance estimated as earnings releases for high-growth companies typically result in ≥5% price movement. Analysts forecast EPS of approximately $2.93 forecasted.
5/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
High importance estimated as earnings releases for major pharma often result in >10% price movement. Q1 2026 earnings release scheduled. Analysts forecast EPS of $0.87 and revenue of $11.35 billion forecasted.
5/6/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly reported Q1 2026 revenue of $19.8 billion (+56% YoY) and non-GAAP EPS of $8.55, beating estimates. The company raised its full-year 2026 revenue guidance to $82-$85 billion, driven by strong sales of Mounjaro and Zepbound. This significant growth and guidance raise is estimated to result in a >10% price impact.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
The U.S. FDA proposed removing tirzepatide, the active ingredient in Mounjaro and Zepbound, from the bulk drug substances list on 2026-04-30, restricting compounded versions. This regulatory protection of market share is estimated to result in a >10% price impact.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Reported Q1 2026 financial results, posting a GAAP Loss per Share of $1.72, which included a $3.62 per share charge from the acquisition of Cidara Therapeutics. Revenue grew 5% to $16.3 billion. The company raised its full-year 2026 guidance; high importance due to guidance raise and acquisition impact, market reaction expected.
4/30/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
High importance estimated as this regulatory change protects core revenue from competition, likely impacting price by >10%. The U.S. FDA proposed to exclude the active ingredients in key Novo Nordisk GLP-1 drugs from the bulk compounding list.
4/30/2026, 12:00:00 AM